Bladder cancer surveillance remains challenging because conventional methods do not fully capture the biological heterogeneity within histologically low-grade urothelial carcinoma (LGUC). We evaluated whether urinary DNA methylation profiling using Bladder EpiCheck™ can identify clinically relevant LGUC subgroups in a retrospective single-center cohort of 134 patients with paired histopathology, urine cytology, and methylation results. Methylation positivity increased across negative histopathology, LGUC, and high-grade urothelial carcinoma (HGUC) (18.4%, 51.4%, and 91.5%, respectively). Within LGUC, 19 of 37 tumors (51.4%) were methylation-positive. Their EpiScores overlapped those of HGUC, whereas methylation-negative LGUCs exhibited scores similar to negative histopathology. Gaussian mixture modeling independently supported a bimodal distribution. Methylation-positive LGUCs demonstrated a higher Ki67 labeling index, more frequent MTAP loss (33.3% vs. 11.8%), and more recurrences, including recurrence as HGUC, than methylation-negative LGUCs. Conventional nuclear morphometry did not distinguish between the two LGUC subgroups. These exploratory findings suggest that urinary DNA methylation may identify a biologically distinct subset of histologically low-grade tumors with selected high-grade-associated features. Prospective external validation is required before methylation status can inform surveillance or treatment decisions.
Bladder cancer surveillance remains challenging due to the limited sensitivity of con-ventional diagnostic methods for detecting biologically aggressive disease, particularly in low-grade urothelial carcinomas (LGUC). This study evaluated the diagnostic per-formance and biological significance of the urinary DNA methylation assay Bladder EpiCheck™ in patients undergoing histopathological evaluation for suspected urothe-lial carcinoma. A retrospective cohort of 134 patients with paired histopathology, urine cytology and Bladder EpiCheck™ results was analyzed. Bladder EpiCheck™ showed excellent performance for high-grade urothelial carcinoma (HGUC) detection, with 91.5% sensitivity, 81.6% specificity and an AUC of 0.876. Methylation scores in-creased with tumor grade and identified two molecular subgroups within LGUC. Methylation-positive LGUCs displayed HGUC-like epigenetic profiles, increased pro-liferation, more frequent MTAP loss and higher recurrence/progression risk, whereas methylation-negative LGUCs resembled benign urothelium and had more favorable outcomes. These findings indicate that urinary DNA methylation provides clinically relevant biological information beyond histological grading and may improve LGUC risk stratification and personalized surveillance.